158 related articles for article (PubMed ID: 21658147)
1. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
Hartman A; van Schaik RH; van der Heiden IP; Broekhuis MJ; Meier M; den Boer ML; Pieters R
Leuk Res; 2010 Feb; 34(2):154-9. PubMed ID: 19467705
[TBL] [Abstract][Full Text] [Related]
4. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
6. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.
Frost BM; Lönnerholm G; Koopmans P; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Uges DR; de Graaf SS
Acta Paediatr; 2003 May; 92(5):551-7. PubMed ID: 12839283
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
Guilhaumou R; Simon N; Quaranta S; Verschuur A; Lacarelle B; Andre N; Solas C
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1191-8. PubMed ID: 21404110
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
[TBL] [Abstract][Full Text] [Related]
9. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
10. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
11. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).
Groninger E; Meeuwsen-de Boer T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
Eur J Cancer; 2005 Jan; 41(1):98-103. PubMed ID: 15617994
[TBL] [Abstract][Full Text] [Related]
12. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.
Lönnerholm G; Frost BM; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Heyman M; Uges DR; de Graaf SS
Br J Haematol; 2008 Aug; 142(4):616-21. PubMed ID: 18537965
[TBL] [Abstract][Full Text] [Related]
13. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia.
Groninger E; Meeuwsen-de Boar T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
Pediatr Res; 2002 Jul; 52(1):113-8. PubMed ID: 12084857
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
17. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
[TBL] [Abstract][Full Text] [Related]
19. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.
Plasschaert SL; Groninger E; Boezen M; Kema I; de Vries EG; Uges D; Veerman AJ; Kamps WA; Vellenga E; de Graaf SS; de Bont ES
Clin Pharmacol Ther; 2004 Sep; 76(3):220-9. PubMed ID: 15371983
[TBL] [Abstract][Full Text] [Related]
20. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
